Keyphrases
Breast Cancer Recurrence
100%
Exemestane
100%
Aromatase Inhibitors
100%
Anastrozole
100%
Hormone-sensitive
100%
Letrozole
83%
No Significant Difference
66%
Adverse Events
50%
Objective Response Rate
50%
Indirect Comparison
50%
Postmenopausal Women
33%
Overall Survival
33%
Progression-free Survival
33%
Time to Progression
33%
Inclusion Criteria
16%
Meta-analysis
16%
Advanced Disease
16%
Metastatic Disease
16%
ErbB2
16%
Serious Adverse Events
16%
Randomized Controlled Clinical Trial
16%
Arthralgia
16%
Synthesis Methods
16%
Metastatic Breast Cancer
16%
Hot Flushes
16%
Network Analysis
16%
Advanced or Metastatic
16%
Head-to-head Comparison
16%
Narrative Synthesis
16%
Hormone Receptor-positive
16%
ER +
16%
Postmenopausal Hormones
16%
Publication Status
16%
Network Meta-analysis
16%
Homogeneity Similarity
16%
Class Effect
16%
Language Status
16%
Quality-adjusted Time without Symptoms or Toxicity
16%
Clinically Meaningful Outcomes
16%
HER2-positive Metastatic Breast Cancer
16%
Nursing and Health Professions
Systematic Review
100%
Breast Cancer
100%
Metastatic Breast Cancer
100%
Tamoxifen
100%
Aromatase Inhibitor
100%
Anastrozole
66%
Exemestane
66%
Letrozole
55%
Adverse Event
44%
Overall Survival
22%
Progression Free Survival
22%
Meta Analysis
11%
Arthralgia
11%
Hot Flush
11%
Metastasis
11%
Hormone Receptor
11%
Network Meta-Analysis
11%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Metastatic Breast Cancer
100%
Tamoxifen
100%
Aromatase Inhibitor
100%
Exemestane
66%
Anastrozole
66%
Letrozole
55%
Adverse Event
44%
Overall Survival
22%
Progression Free Survival
22%
Hormone Receptor
11%
Metastasis
11%
Controlled Clinical Trial
11%
Arthralgia
11%
Hot Flush
11%